For Preexisting Immune Complex Or Auto-immune Disease Patents (Class 436/506)
  • Patent number: 9599608
    Abstract: The present invention provides a means and a method for specifically measuring a substance such as a small substance with high sensitivity by a sandwich method. Specifically, the present invention provides an antibody capable of specifically binding to an affinity complex and a method of measuring of the affinity complex comprising measuring the affinity complex using the antibody capable of specifically binding to the affinity complex. The antibody of the present invention may be a full-length antibody. The antibody of the present invention may also have a region derived from an immunoglobulin from an animal having an ability of gene conversion (e.g., a complementarity-determining region, a framework region, or a variable region). Examples of at least one factor that constitutes the affinity complex include a small substance or a protein (e.g., antibody).
    Type: Grant
    Filed: July 4, 2012
    Date of Patent: March 21, 2017
    Assignee: FUJIREBIO INC.
    Inventors: Kazuya Omi, Tsuyoshi Ando, Yoshiaki Uchida, Katsutoshi Goishi, Yoshie Goishi, Asako Oka, Takashi Shirakawa, Takuya Sakyu
  • Patent number: 9335339
    Abstract: The present invention relates to a specimen testing device and method thereof, and it is an object of the present invention to provide a compact and reliable specimen testing device and method thereof.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: May 10, 2016
    Assignee: UNIVERSAL BIO RESEARCH CO., LTD.
    Inventor: Hideji Tajima
  • Patent number: 9096674
    Abstract: The present invention is in the area of coagulation analysis and relates to antibodies which bind specifically to an immune complex of prothrombin fragment F2/F1+2 and an F2/F1+2 neoepitope-specific antibody fragment, and to the preparation and the use thereof in methods for determining F2/F1+2.
    Type: Grant
    Filed: September 24, 2009
    Date of Patent: August 4, 2015
    Assignee: Siemens Healthcare Diagnostics Products GmbH
    Inventors: Matthias Ehm, Bodo Fischer, Harald Althaus, Roland Barten
  • Patent number: 9012372
    Abstract: The invention relates to the field of biomedical and pharmacological research, in particular to the area of immunology, allergies and autoimmune diseases. The inventors have shown that SWAP-70 is a higher-level regulator for STAT-6 and BCL-6, the regulator being specific for IgE production in B-cells by amplifying the effect of STAT-6 and antagonizing the effect of BCL-6. The inventors have observed no influence of SWAP-70 on the expression of other genes that are likewise regulated by STAT-6 and/or BCL-6. In summary, it can be concluded that SWAP-70 positively regulates IgE production by shifting the interaction of the two antagonists STAT-6 and BCL-6 with regulatory elements of the IgE gene in favor of the activator STAT-6. Based on said findings, the invention provides a screening method which allows for identifying novel active agents that specifically inhibit IgE production.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: April 21, 2015
    Assignee: Albonia Biotech, Inc.
    Inventors: Rolf Jessberger, Tatsiana Audzevich
  • Patent number: 9005982
    Abstract: The present disclosure is generally related to pulmonary autoantigens. The disclosure provides methods and kits for assessing whether a subject has or is predisposed to interstitial lung disease. Additionally the present disclosure provides methods of treatment and animal models of interstitial lung disease.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: April 14, 2015
    Assignee: The Regents of the University of California
    Inventors: Mark S. Anderson, Anthony K. Shum
  • Patent number: 8956823
    Abstract: An anti-antibody reagent for use in a competitive or sandwich simplex or multiplex assay, said reagent comprising one or more labeled anti-antibodies for the primary antibodies to be determined in the assay, the reagent further comprising a corresponding unlabeled anti-antibody in an excess or near excess concentration with respect to their binding partners.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: February 17, 2015
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: William F. Link, Renato B. Del Rosario, Randy Sweet, David L. King
  • Patent number: 8951743
    Abstract: The present invention stems from the finding that the extracellular domain of CD31 proteins present on blood leukocytes is shed and released in the circulation as a soluble form of CD31. A method for detecting shed CD31 is further disclosed. The invention therefore relates to a method for detecting a shed ectodomain of a transmembrane protein such as CD31 and to the use of such a method as a diagnostic tool. The invention further provides methods for determining whether a candidate protein is part of a molecular complex.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: February 10, 2015
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Giuseppina Caligiuri, Antonino Nicoletti
  • Patent number: 8927290
    Abstract: Provided herein are compositions comprising native and denatured human leukocyte antigens (HLA) and methods of making said compositions. Also provided herein are methods and kits for the detection of antibodies to native HLAs.
    Type: Grant
    Filed: February 16, 2011
    Date of Patent: January 6, 2015
    Assignee: One Lambda, Inc.
    Inventors: Adam Idica, Chun-Tsan Deng, Paul I. Terasaki
  • Patent number: 8900880
    Abstract: The present invention relates to an antigenically effective peptide comprising, from the amino to the carboxylic terminal, the amino acid sequence: G P P W W P P I C D P P Q P S K T Q G Q S X1 G Q S X2 G X3 G X4 G X5 G X6 G X7 G K G K S X8 D K Q X9 K P G G P W X10 P E P (SEQ ID No. 1), wherein the amino acids X1-X10 are selected independently from an arginine residue or a citrulline residue and at least one of X1-X10 is a citrulline residue, or a functional fragment thereof and uses thereof.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: December 2, 2014
    Assignee: Toscana Biomarkers S.R.L.
    Inventors: Paola Migliorini, Federico Pratesi
  • Publication number: 20140287941
    Abstract: Imaging a sample that includes phototransformable optical labels (“PTOLs”) with an optical system having a diffraction-limited resolution volume (DLRV), includes providing activation radiation to the PTOLs to activate a statistical subset of the PTOLs. A density of the PTOLs of the activated subset is less than an inverse of the DLRV. Excitation radiation is provided to the activated subset to excite activated PTOLs. Radiation emitted from the activated and excited PTOLs located at different focal planes of the optical system within the sample is detected with the optical system. The preceding steps are repeated one or more times, each time activating a different statistical subset of the plurality of PTOLs. Three-dimensional locations within the sample are determined, with a sub-diffraction-limited accuracy, of the activated and excited PTOLs based on the radiation emitted from the activated and excited PTOLs that is detected from the different focal planes of the optical system.
    Type: Application
    Filed: October 28, 2013
    Publication date: September 25, 2014
    Applicant: Hestzig LLC
    Inventors: Robert Eric Betzig, Harald F. Hess
  • Patent number: 8828667
    Abstract: Compositions are provided according to embodiments of the present invention which include an isolated antibody or antigen binding antibody fragment characterized by binding specificity for a conjugate which is a reaction product of a protein moiety and an isocyanate moiety. Methods of detecting diisocyanate-protein conjugates in a sample are provided according to embodiments of the present invention which include contacting a sample with one or more isolated antibodies or antigen binding antibody fragments characterized by binding specificity for corresponding diisocyanate-protein conjugate antigens.
    Type: Grant
    Filed: October 12, 2009
    Date of Patent: September 9, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Paul D. Siegel, Tinashe Blessing Ruwona, Donald H. Beezhold, Victor Johnson, Detlef Schmechel
  • Patent number: 8822168
    Abstract: The present invention includes assays and kits for detecting the assembly of an RNA binding protein-RNA complex and for detecting the activity of an RNA binding protein.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: September 2, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Gideon Dreyfuss, Lili Wan, Elizabeth Ottinger
  • Patent number: 8759114
    Abstract: Peptides useful in determining the presence of autoantibodies in patients suffering from rheumatoid arthritis are disclosed.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: June 24, 2014
    Assignee: Stichting Voor de Technische Wetenschappen
    Inventors: Waltherus Jacobus Wilhelmus Van Venrooij, Jan Wouter Drijfhout, Martinus Adrianus Maria Van Boekel, Gerardus Jozef Maria Pruijn
  • Patent number: 8741662
    Abstract: Methods and kits for diagnosis and prognosis using biomarkers comprising albumin-bound protein/peptide complex (ABPPC).
    Type: Grant
    Filed: June 14, 2007
    Date of Patent: June 3, 2014
    Assignee: The Johns Hopkin University
    Inventors: Jennifer E. Van Eyk, Rebekah Lynn Gundry, Robert J. Cotter
  • Patent number: 8728748
    Abstract: The invention relates to in vitro method for quantitating the antibodies specific for High mobility group box I (HMGB1) contained in a sample, in particular a serum sample or a cerebrospinal fluid sample obtained from a patient, and the use of this method in the prognostic and/or diagnosis of neurological disorders. These methods are in particular applicable to the monitoring of the human immunodeficiency virus (HIV) infection of a subject who is known to be infected with HIV and in the prognostic and/or diagnostic of the state of progression of Acquired immune deficiency syndrome (AIDS) or the state of progression toward AIDS, in particular the state of progression or the state of progression toward neurological disorders associated with AIDS. Finally, the invention is also about method to determine the immune deficiency or level of immune activation of a patient, in particular a HIV-infected patient.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: May 20, 2014
    Assignee: Institut Pasteur
    Inventors: Marie-Lise Gougeon, Beatrice Poirier-Beaudoin, Valerie Seffer, Hela Saidi
  • Patent number: 8716030
    Abstract: Embodiments of the present invention provide for novel peptides of use for detection and/or inhibition of anti-?1-adrenergic receptor antibodies. Certain embodiments concern uses of cyclic and/or linear peptides. In other embodiments, the present invention relates to novel peptides of use in diagnostic and/or pharmaceutical compositions. Some embodiments concern diagnosing and/or treating cardiac conditions. Cardiac conditions of the instant invention can concern infectious heart disease, non-infectious heart disease, ischemic heart disease, non-ischemic heart disease, inflammatory heart disease, myocarditis, cardiac dilatation, idiopathic cardiomyopathy, idiopathic dilated cardiomyopathy, immune-cardiomyopathy, heart failure, and any cardiac arrhythmia condition.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: May 6, 2014
    Assignee: Julius-Maximillians-Universitat Wurzburg, A Germany University
    Inventors: Roland Jahns, Valérie Jahns, Martin J. Lohse, Dieter Palm
  • Patent number: 8715682
    Abstract: Embodiments of the present invention provide for novel peptides of use for detection and/or inhibition of anti-?1-adrenergic receptor antibodies. Certain embodiments concern uses of cyclic and/or linear peptides. In other embodiments, the present invention relates to novel peptides of use in diagnostic and/or pharmaceutical compositions. Some embodiments concern diagnosing and/or treating cardiac conditions. Cardiac conditions of the instant invention can concern infectious heart disease, non-infectious heart disease, ischemic heart disease, non-ischemic heart disease, inflammatory heart disease, myocarditis, cardiac dilatation, idiopathic cardiomyopathy, idiopathic dilated cardiomyopathy, immune-cardiomyopathy, heart failure, and any cardiac arrhythmia condition.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: May 6, 2014
    Assignee: Julius-Mazimillians-Universitat Wurzburg, a German University
    Inventors: Roland Jahns, Valérie Jahns, Martin J. Lohse, Dieter Palm
  • Publication number: 20140120156
    Abstract: The present application relates to methods of producing exosomes. The application also provides a method for preparing a protein composition comprising culturing an exosome-producing cell expressing a Nef-fusion protein comprising a Nef-derived peptide fused to a protein of interest; isolating exosomes from the exosome-producing cell culture; and purifying the protein of interest from the isolated exosomes. The application further discloses compositions that comprise exosomes containing the Nef-fusion protein, as well as methods of using the Nef-fusion protein and exosomes containing the Nef-fusion protein.
    Type: Application
    Filed: September 6, 2013
    Publication date: May 1, 2014
    Inventors: Vincent Craig BOND, Michael POWELL, MingBo HUANG, Syed ALI
  • Patent number: 8709735
    Abstract: The present invention provides ?2 microglobulin as a biomarker for qualifying or assessing peripheral artery disease in a subject.
    Type: Grant
    Filed: January 16, 2013
    Date of Patent: April 29, 2014
    Assignees: Vermillion, Inc., Board of Trustees of of the Leland Stanford Junior University
    Inventors: John P. Cooke, Eric T. Fung, Elichiro Kimura
  • Patent number: 8685662
    Abstract: The present invention pertains to a method for in vitro prognosticating and/or diagnosing cerebral cerebral malaria, wherein said method comprises a step of detecting non-erythroid spectrin or fragments thereof, and/or antibodies directed against non-erythroid spectrin, in a biological sample. Reagents and kits for performing this method are also disclosed.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: April 1, 2014
    Assignees: Institut Pasteur, Universite Pierre et Marie Curie (Paris 6)
    Inventors: Sylviane Pied, Vincent Guiyedi, Pierre-André Cazenave, Maryvonne Kombila, Youri Chanseaud
  • Patent number: 8668978
    Abstract: Nanosubstrates as biosensors, methods of making such nanosubstrates, and methods of using such nanosubstrates to detect biomarkers are described.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: March 11, 2014
    Assignee: Northeastern University
    Inventors: Asanterabi Malima, Ahmed Busnaina, Salome Siavoshi, Sivasubramanian Somu, Cihan Yilmaz, Tiziana Musacchio, Jaydev Upponi, Vladimir Torchilin
  • Patent number: 8663938
    Abstract: Methods and compositions are provided for detection of biological substances in nasal specimen.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: March 4, 2014
    Inventor: Robert I. Henkin
  • Patent number: 8628932
    Abstract: The invention is directed to methods of screening for HLA antibodies comprising detecting antibodies specific for native HLA antigens and denatured HLA antigens. The invention also provides for methods of removing antibodies specific for denatured HLA antigens or antibodies specific for native HLA antigens from a serum sample. In addition, the invention also provides for method of predicting whether a transplant recipient has an increased risk for rejecting the transplanted organ.
    Type: Grant
    Filed: March 9, 2011
    Date of Patent: January 14, 2014
    Assignee: One Lambda
    Inventors: Jar-How Lee, Rui Pei, Thoa Nong
  • Patent number: 8623610
    Abstract: Chondroitin sulfate polysaccharides with defined sulfation patterns can be synthesized. These chondroitin polysaccharides can be used to identify chondroitin sulfate binding proteins. Further, compounds that modulate the activity of chondroitin sulfate binding proteins can be identified. For example, TNF-? was found to bind specifically to CS-E and CS-E can be used to modulate the interaction of TNF-? with the TNF receptor.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: January 7, 2014
    Assignee: California Institute of Technology
    Inventors: Cristal I. Gama, Sarah E. Tully, Linda C. Hsieh-Wilson
  • Publication number: 20140004181
    Abstract: The present application relates to methods of producing exosomes. The application also provides a method for preparing a protein composition comprising culturing an exosome-producing cell expressing a Nef-fusion protein comprising a Nef-derived peptide fused to a protein of interest; isolating exosomes from the exosome-producing cell culture; and purifying the protein of interest from the isolated exosomes. The application further discloses compositions that comprise exosomes containing the Nef-fusion protein, as well as methods of using the Nef-fusion protein and exosomes containing the Nef-fusion protein.
    Type: Application
    Filed: September 6, 2013
    Publication date: January 2, 2014
    Applicant: Morehouse School of Medicine
    Inventors: Vincent Craig BOND, Michael Powell, Ming Bo Huang, Syed Ali
  • Patent number: 8609432
    Abstract: Disclosed is a rapid, non-invasive and highly specific and sensitive diagnostic assay for the identification of individuals with autoimmune chronic urticaria, which makes use of CD203c, and in some embodiments, additional proteins, as a marker for the disease. Test kits for diagnosis of an individual suspected of having autoimmune chronic urticaria are also disclosed. Also disclosed are a method of identifying compounds useful for treating autoimmune chronic urticaria and a method of treating autoimmune chronic urticaria.
    Type: Grant
    Filed: August 7, 2012
    Date of Patent: December 17, 2013
    Inventors: Ronald Joseph Harbeck, Karen Mary Andrews, Donald MacGlashan
  • Patent number: 8609356
    Abstract: The invention relates to an in vitro method for detecting pulmonary arterial hypertension (PAHT), or the risk of developing PAHT, which includes determining the presence and/or amount of anti-tenascin C antibodies in a biological sample from a patient.
    Type: Grant
    Filed: April 10, 2009
    Date of Patent: December 17, 2013
    Assignees: Assistance Publique-Hopitaux de Paris, Universite Paris Descartes, Universite Paris-Sud 11
    Inventors: Luc Mouthon, Marc Humbert, Mathieu Tamby
  • Patent number: 8603766
    Abstract: Compositions and methods for modulating human immunodeficiency virus (HIV) infection involving substances that inhibit the ability of high mobility box 1 (HMGB1) protein to interact with natural killer (NK) cells. Therapeutic compositions comprising antibodies and drugs, such as glycyrrhizin, which bind to HMGB1. Methods of detecting or monitoring HIV infection involving detection or quantitation of HMGB1 or antibodies specific for HMGB1 in a biological sample.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: December 10, 2013
    Assignee: Institut Pasteur
    Inventors: Marie-Lise Gougeon, Hela Saidi, Maria-Therese Melki, Beatrice Poirier-Beaudoin, Valerie Seffer
  • Patent number: 8563327
    Abstract: The present invention provides, as a novel diagnosis marker for type 1 diabetes mellitus, a type 1 diabetes mellitus diagnostic composition comprising alanyl-tRNA synthetase, glycyl-tRNA synthetase, asparaginyl-tRNA synthetase, or tryptophanyl-tRNA synthetase, a diagnostic kit comprising the same, and a diagnostic method using the same. The composition, the kit, and the method, according to the present invention, may be used for early diagnosis and confirmed diagnosis of type 1 diabetes mellitus because type 1 diabetes mellitus can be easily diagnosed from a patient sample.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: October 22, 2013
    Assignees: Seoul National University Hospital, SNU R&DB Foundation
    Inventors: Sang Gyu Park, Kyong Soo Park, Sunghoon Kim
  • Patent number: 8557603
    Abstract: Provided herein are synthetic peptides, methods and kits for easy detecting or diagnosing an autoimmune disease, particularly, Henoch-Schönlein purpura (HSP), based on the detection of autoimmune antibodies with peptides derived from ?-2-glycoprotein-1 (?2-GPI).
    Type: Grant
    Filed: January 2, 2009
    Date of Patent: October 15, 2013
    Assignee: FlySun Development Co. Ltd.
    Inventors: Bor-Luen Chiang, Yao-Hsu Yang, Chung-Sheng Huang
  • Publication number: 20130203066
    Abstract: The present application relates to the isolation and analysis of populations of microvesicles and the identification of invasive microvesicles in the populations such as populations of microvesicles that are shed by tumor cells. Invasive microvesicles from tumor cells contain a variety of specific proteins, such as ARF6.
    Type: Application
    Filed: January 29, 2013
    Publication date: August 8, 2013
    Applicant: UNIVERSITY OF NOTRE DAME
    Inventor: University of Notre Dame
  • Patent number: 8481332
    Abstract: A liposomal composition, preferably a vaccine, comprising liposomes formed of liposome forming compounds, containing coentrapped polysaccharide antigen and T-cell dependent protein carrier, such as tetanus toxoid or diphtheria toxin modified to render it non-toxic. The invention is of use in the production of vaccines against Haemophilus influenzae, Streptococcus pneumoniae or Neisseria meningitidis.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: July 9, 2013
    Assignee: Stichting Voor de Technische Wetenshappen
    Inventors: Waltherus Jacobus Wilhelmus Van Venrooij, Jan Wouter Drijfhout, Martinus Adrianus Maria Van Boekel, Gerardus Jozef Maria Pruijn
  • Patent number: 8404456
    Abstract: The present invention provides compositions and methods for treating or preventing antibody mediated graft rejection and blood typing.
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: March 26, 2013
    Assignee: AbSorber AB
    Inventors: Jan Holgersson, Jining Liu, Linda Lindberg, Per Grufman
  • Patent number: 8367398
    Abstract: Provided is a microfluidic apparatus including: a microfluidic structure for providing spaces for receiving a fluid and for forming channels, through which the fluid flows; and valves for controlling the flow of fluid through the channels in the microfluidic apparatus. The microfluidic structure includes: a sample chamber; a sample separation unit receiving the sample from the sample chamber and separating a supernatant from the sample by using a centrifugal force; a testing unit receiving the supernatant from the sample separation unit for detecting a specimen from the supernatant using an antigen-antibody reaction, and a quality control chamber for identifying reliability of the test.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: February 5, 2013
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Beom Seok Lee, Ji Won Kim, Jeong Gun Lee, Kui Hyun Kim
  • Patent number: 8338188
    Abstract: The present invention relates to the identification and use of proteins with clinical relevance to rheumatoid arthritis (RA). In particular, the invention provides the identity of marker proteins that specifically react with RA-associated autoantibodies. Also provided are methods, arrays and kits for using these proteins in the diagnosis of RA, and in the selection and/or monitoring of treatment regimens.
    Type: Grant
    Filed: May 12, 2009
    Date of Patent: December 25, 2012
    Assignee: Inserm (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Jean Roudier, Isabelle Auger
  • Patent number: 8338117
    Abstract: The present invention is in the field of autoimmunity. More specifically, the present invention relates to the detection of autoantibodies to domain 4 of beta 2-glycoprotein I (?2-GPI) as an indicator for atherosclerosis.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: December 25, 2012
    Assignee: Inova Diagnostics, Inc.
    Inventors: G. Michael Iverson, Walter L. Binder, Gary L. Norman
  • Patent number: 8334105
    Abstract: The invention provides methods for identifying modulators of cardiac troponin I activity as well as methods for using N-terminally truncated forms of cTnI to monitor the function of the circulatory system in general, and the heart in particular, of an organism such as man. Additionally, the invention provides methods of treating circulatory diseases, disorders or conditions, such as cardiac diseases and conditions, by administering a therapeutically effective amount of a modulator of the N-terminal structure of cTnI, such as a molecule capable of binding to the N-terminus of full-length cTnI, a molecule that modulates cTnI phosphorylation and/or N-terminal proteolytic cleavage, or by administering N-terminally truncated cTnI or a polynucleotide encoding that protein or polypeptide.
    Type: Grant
    Filed: January 7, 2009
    Date of Patent: December 18, 2012
    Assignee: Northshore University Healthsystem
    Inventor: Jian-Ping Jin
  • Patent number: 8334146
    Abstract: The binding specificity of at least one plasma protein suspended or dissolved in a liquid medium is altered by exposing the protein to an oxidizing agent or an electric current sufficient to alter its binding specificity. A masked protein such as an autoantibody can be recovered from blood or blood products or extracts by oxidizing the protein to change its binding specificity.
    Type: Grant
    Filed: April 23, 2008
    Date of Patent: December 18, 2012
    Assignee: Redox-Reactive Reagents LLC
    Inventor: John A. McIntyre
  • Patent number: 8278119
    Abstract: By detecting an antibody which immunologically reacts with amylase ?2-A in a sample, AIP or FT1DM is examined or the possibility of developing FT1DM is determined. For instance, detection of this antibody is carried out by an immunological method using an antigen which immunologically reacts with this antibody. The antigen is preferably a partial fragment containing the amino acid sequence of amino acid numbers 299 to 511 of human amylase ?2-A (SEQ ID NO: 1).
    Type: Grant
    Filed: May 2, 2008
    Date of Patent: October 2, 2012
    Assignees: University of Yamanashi, Cosmic Corporation
    Inventors: Tetsuro Kobayashi, Toyoshi Endo, Atsushi Sakuraoka
  • Patent number: 8263355
    Abstract: Disclosed is a rapid, non-invasive and highly specific and sensitive diagnostic assay for the identification of individuals with autoimmune chronic urticaria, which makes use of CD203c, and in some embodiments, additional proteins, as a marker for the disease. Test kits for diagnosis of an individual suspected of having autoimmune chronic urticaria are also disclosed. Also disclosed are a method of identifying compounds useful for treating autoimmune chronic urticaria and a method of treating autoimmune chronic urticaria.
    Type: Grant
    Filed: June 29, 2010
    Date of Patent: September 11, 2012
    Inventors: Ronald Joseph Harbeck, Karen Mary Andrews, Donald MacGlashan, Jr.
  • Patent number: 8183055
    Abstract: The present invention relates to a peptide aptamer which mimics particularly the human platelet antigene HPA-Ia epitope present on the platelet GPIIb/IIIa molecules and which is capable of neutralizing the binding of HPA-I a specific antibodies (anti-HPA-1 a). This peptide aptamer is advantageously used in a method for detecting and identifying HPA-I a specific antibodies in human serum, in a diagnostic kit for screening and identifying antibodies, in an immunoassay and a pharmaceutical composition.
    Type: Grant
    Filed: February 7, 2007
    Date of Patent: May 22, 2012
    Assignee: Stiftung für Diagnostische Forschung
    Inventors: Dominique Rigal, Julien Thibaut, Gemain Gillet, Yves Merieux
  • Patent number: 8183056
    Abstract: A method for determining the risk of an individual of suffering from inflammation, opportunistic infection or disruption of immunoglobulin metabolism, comprising (a) determining the level of fragmentation or modification of Fc function of immunoglobulins in a sample taken from the individual and (b) determining thereby the risk of inflammation, impaired immune response or opportunistic infection. The invention also provides the use of a trypsin inhibitor in the manufacture of a medicament for use in the treatment or prevention of a disorder associated with elevated trypsin activity which is correlated with IgG fragmentation or modification.
    Type: Grant
    Filed: October 15, 2008
    Date of Patent: May 22, 2012
    Inventor: Ivan Mikhailovich Petyaev
  • Patent number: 8178358
    Abstract: The present invention provides a method for diagnosis or prognosis of IgA nephropathy in a subject based on detection of the expression level of one or more biomarker genes selected from the group consisting of thymosin ?4 (Tmsb4), serine or cysteine proteinase inhibitor clade E member 2 (Serpine2), secreted phosphoprotein 1 (OPN), butyrophilin-like-2 (BTNL2), S100 calcium binding protein A8 (S100A8), Cystatin C (CysC), and any combination thereof.
    Type: Grant
    Filed: January 28, 2010
    Date of Patent: May 15, 2012
    Assignee: National Defense Medical Center
    Inventors: Ann Chen, Shuk-Man Ka
  • Patent number: 8173382
    Abstract: The invention provides among other things methods and kits based on assaying for cardiac troponin autoantibodies, either in conjunction with an assay for cardiac troponin and/or as an independent indicator of cardiac pathology, such as myocarditis, cardiomyopathy, and/or ischemic heart disease. Assay methods of the invention can be employed among other things to identify cardiac pathology, or risk thereof, in subjects who have an autoimmune disease or who are related to an individual with an autoimmune disease. In particular embodiments, the invention also provides a method of determining whether a subject having, or at risk for, a cardiac pathology is a candidate for immunosuppressive therapy or immunoabsorption therapy. The invention also provides kits and kit components that are useful for performing the methods of the invention.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: May 8, 2012
    Assignee: Abbott Laboratories
    Inventors: Phillip G. Mattingly, Maciej Adamczyk, Roy Jeffrey Brashear, Robert C. Doss
  • Patent number: 8153443
    Abstract: This invention provides methods of diagnosing or predicting susceptibility to Crohn's Disease by determining the presence or absence of genetic variants. In one embodiment, the present invention provides methods to diagnose and/or predict susceptibility to Crohn's Disease in an individual by determining the presence or absence of anti-Cbir1 reactivity and the presence or absence of TLR5 risk variants. In another embodiment, the present invention provides methods to diagnose Crohn's Disease by determining the presence or absence of NFKB1 haplotype H3 and/or ASCA expression. In another embodiment, the present invention provides methods of diagnosing Crohn's Disease by determining the presence or absence of Cbir1 specific peripheral blood T cell proliferation.
    Type: Grant
    Filed: May 9, 2008
    Date of Patent: April 10, 2012
    Assignees: Cedars-Sinai Medical Center, The UAB Research Foundation
    Inventors: Kent D. Taylor, Jerome I. Rotter, Charles O. Elson, Stephan R. Targan
  • Patent number: 8129132
    Abstract: A method of screening a sample of body fluid obtained from an animal subject for analyte autoantibodies reactive with one or more antigenic molecules selected from pancreatic islet cell antigenic molecules and insulin, or one or more variants, analogues, derivatives or fragments thereof, and a kit for use in such a method.
    Type: Grant
    Filed: November 26, 2002
    Date of Patent: March 6, 2012
    Assignee: RSR Limited
    Inventors: Bernard Rees Smith, Jadwiga Furmaniak, Michael Powell
  • Patent number: 8110374
    Abstract: The invention relates to a method and an immunological test kit for predicting the risk of transplant rejection by detecting anti-AT1 receptor auto-antibodies in biological materials of a patient to be examined, e.g. by an immune reaction with the AT1 receptor or functionally analogous peptides or proteins thereof. The invention is also directed to the use of the AT1 receptor or functionally analogous peptides or proteins in order to predict (diagnose) the risk of transplant rejection. Said risk exists if anti-AT1 receptor auto-antibodies can be detected in such biological materials, e.g. in body fluids or tissues.
    Type: Grant
    Filed: May 13, 2002
    Date of Patent: February 7, 2012
    Assignee: Cell Trend GmbH
    Inventors: Kai Schulze-Forster, Harald Heidecke
  • Publication number: 20120009566
    Abstract: A bioassay employing a first group including a lanthanide ion carrier chelate and a first recognition element, a second group including an antenna ligand and a second recognition element; where the lanthanide ion carrier chelate binds strongly to lanthanide, or the lanthanide ion carrier chelate binds moderately to lanthanide, and an agent complexing the lanthanide ion is additionally employed at a concentration of at least 1 pmol/l. The antenna ligand binds weakly to the lanthanide ion. Analyte recognition by the first recognition element and by the second recognition element results in either chelate complementation and increased fluorescence, or chelate discomplementation and decreased fluorescence.
    Type: Application
    Filed: March 23, 2010
    Publication date: January 12, 2012
    Inventors: Tero Soukka, Urpo Lamminmaki
  • Patent number: 8088630
    Abstract: Embodiments of the present invention relate to devices and methods for detecting cellular products using detection particles having product-specific detection reagents and having a characteristic spectral feature. In particular, devices and methods are provided for measuring secreted cellular products including cytokines. Detection substrates, include microwells having product-specific capture reagents thereon or comprising hydrophobic membranes are described having greater capability to detect products from individual cells in a mixture of heterogeneous cells. With the use of multiple detection particles, multiple cellular products can be detected in a single well. Additionally, using the inherent spectral properties of detection particles, no enzymatic reactions are needed to visualize a secreted product, thereby increasing the sensitivity, reproducibility and ease of use.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: January 3, 2012
    Inventors: Paul V. Lehmann, Alexey Y. Karulin, Thomas Oliver Kleen
  • Patent number: 8084272
    Abstract: The invention is directed to methods and devices for reducing interference from heterophile antibodies in an analyte immunoassay. In one embodiment, the invention is to a method comprising the steps of (a) amending a biological sample such as a whole blood sample with non-human IgM or fragments thereof by dissolving into said sample a dry reagent to yield a non-human IgM concentration of at least about 20 ?g/mL or equivalent fragment concentration; and (b) performing an electrochemical immunoassay on the amended sample to determine the concentration of said analyte in said sample. Preferably, the sample is amended with IgG or fragments thereof in addition to the IgM of fragments thereof.
    Type: Grant
    Filed: March 25, 2009
    Date of Patent: December 27, 2011
    Assignee: Abbott Point of Care Inc.
    Inventors: John Lewis Emerson Campbell, John Emegbero Omakor